Litigation Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2015)
✉ Email this page to a colleague
Orexo AB v. Actavis Elizabeth LLC (D. Del. 2015)
| Docket | ⤷ Sign Up | Date Filed | 2015-10-30 |
| Court | District Court, D. Delaware | Date Terminated | 2019-01-10 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | Defendant | Referred To | Sherry R. Fallon |
| Parties | ACTAVIS ELIZABETH LLC; OREXO US INC. | ||
| Patents | 8,454,996; 8,470,361; 8,658,198; 8,940,330; 9,259,421; 9,439,900 | ||
| Attorneys | Jack B. Blumenfeld; Karl A. Leonard | ||
| Firms | Morris, Nichols, Arsht & Tunnell; Phillips, Goldman, McLaughlin & Hall, P.A. | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Orexo AB v. Actavis Elizabeth LLC
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2015-12-10 | 14 | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,658,198; 8,470,361; . (Phillips,…2015 10 January 2019 1:15-cv-00996 830 Patent Defendant District Court, D. Delaware | External link to document | |
| 2016-01-13 | 19 | 21, 2015. Date of Expiration of Patent: September 24, 2019 (8,454,996) and September 18, 2032 (8,940,330… Amended Supplemental information for patent cases involving an Abbreviated New Drug Application…2015 10 January 2019 1:15-cv-00996 830 Patent Defendant District Court, D. Delaware | External link to document | |
| 2019-01-09 | 36 | .I. 250 (D. Del. 2016) 4 U.S. Patent 8,454,996 5 U.S. Patent 8,940,330 6 Teva Pharmaceuticals…relating to the ’330 patent should be the same as in Zubsolv I relating to the ’330 patent.”); see also Orexo…Zubsolv I, II, III, and VIII, after patent expiration of the ’330 patent (2032) and enjoining Actavis from… ‘330 patent, the parties agree that Zubsolv IV-VII, and VIII as it relates to the ‘421 patent, should…stipulated judgements. 7 The patents at issue in Zubsolv IV-VII (U.S. Patents 9,259,421 and 9,439,900) expire | External link to document | |
| 2019-01-10 | 37 | infringement of U.S. Patent Nos. 8,454,996 (“the ’996 patent”) and 8,940,330 (“the 330 patent’), based on the…of 7 PagelD #: 243 Patent Nos. 9,259,421 (“the ’421 patent”) and the ’330 patent, based on the filing… of the ’996 patent not invalid and infringed, and the asserted claims of the ’330 patent invalid; WHEREAS…complaints alleging infringement of the °996 patent and °330 patent, based on the filing by Actavis of ANDA…’996 patent are valid and Actavis’s ANDA 208450 infringes the asserted claims of the ’996 patent (C.A. | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
